Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL
NCT ID: NCT03574701
Last Updated: 2019-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2016-05-25
2022-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Vitamin has shown promise from both animal and human studies. However, none has studied the benefits of topical application of vitamin A. This study will be the first to examine this effect.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.
NCT05002530
Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000114
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00065455
Alpha Lipoic Acid in Geographic Atrophy
NCT02613572
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
NCT01521793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To determine if there is an improvement in olfactory function following the use of intranasal Vitamin A in patients with post-inflammatory and/or post-traumatic olfactory loss.
2. Hypothesis
There a significant improvement in olfactory function in patients with olfactory loss using intranasal vitamin A when compared with patients with olfactory loss not using intranasal vitamin A
Null Hypothesis There is no significant improvement in olfactory function in patients with olfactory loss using intranasal vitamin A when compared with patients with olfactory loss not using intranasal vitamin A
3. Justification
To treat post inflammatory and post-traumatic olfactory loss, a few controlled studies have shown a positive effect of a specific therapy for olfactory loss, such as olfactory training (using repeated intensive stimulation of the olfactory system and the use of prednisone. Other drugs studied like Vitamin B and Zinc, have either been insufficiently studied or showed no significant effect on olfactory loss.
The use of Retinoic acid (Vitamin A), a fat-soluble vitamin, in the treatment of olfactory loss has been previously studied in both animal and human models and showed promise. However, no study has examined the use of topical administration of vitamin A. This study will be the first to examine this effect.
4. Objectives
Primary Objective To determine if there is an improvement in olfactory function following the use of intranasal Vitamin A in patients with post-inflammatory and/or post-traumatic olfactory loss.
Secondary Objectives To determine if patient quality of life is improved/affected by the use of intranasal vitamin A.
5. Research Method This is a Single blind Randomized Control Trial.
Procedure
The study population will be consecutive patients diagnosed with loss of olfactory function. It will be a single blind randomized control trial. Allocation concealment will be ensured by the use of sequentially numbered, opaque, sealed envelopes. An assessor blinded to which patient is using vitamin A will assess the primary outcome.
Consent will be obtained for this study following diagnosis of the patient. After diagnosis, the patient will be sent a consent form and will be recruited on the next clinic visit.
Screening: After diagnosis, there will be a screening period; inclusion/exclusion criteria for the study participation will be checked. Subjects who satisfy these criteria will be invited to participate in the study. The consent forms will be sent to them via email and their consent will be recorded.
Blinding: The study will be single-blinded study. The patients will be randomized into 3 arms/groups. An assessor blinded to which patient is using vitamin A will assess the primary outcome.
Study Arms/Groups: The patients will be randomized into 3 groups using the sealed envelope method. Each patient will be his or her own control. There will be two possible scenarios resulting from randomization:
* Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils. Olfactory retraining is a validated and effective method of improving olfaction in patients with olfactory loss and is currently being used at our centre as standard of care. It involves smelling 4 scented oils for 40 minutes everyday for the duration of the study. This is performed by the patients. They will also receive their standard of care budesonide (Pulmicort) for their sinonasal disease. The Vitamin A will be mixed with the budesonide and applied using the mucosal atomization device (MAD). This is a device used to apply intranasal medication. It reduces the medication to tiny droplets so they can reach all parts of the nose and sinuses.
* Group B: This study group will receive Vitamin A and budesonide only. They will not receive olfactory retraining. These will also be applied using the MAD
* Group C: This study group will receive only standard of care budesonide. The medication will also be applied using the MAD.
Patients will also continue to receive all other standard of care medication and procedures as necessary.
6. Statistical Analysis
Sample size calculations According to the study conducted by Hummel et al, a the mean olfactory test (TDI) score was 19 with a standard deviation of 6.4. In order to have an 80% chance of detecting a clinically significant 6 point improvement in olfactory test (TDI) scores at a significant level of 5%, 108 patients will be required. This will be 36 patients per group. There is an approximately 10% drop out rate in studies conducted at the St Paul's sinus centre. Accounting for this drop out rate, a total of 120 participants (40 participants per group) will be required to conduct the study.
Statistical Comparisons Descriptive analysis will be used to describe demographic and some clinical outcomes. Mean, median and standard deviations will be used to describe these outcomes. The primary objective of this study is to compare olfactory function before and after the respective interventions among participants in the three groups. The dichotomous and continuous outcomes will be analyzed using Pearson Chi-squared test and analysis of variance (ANOVA). Analysis of variance will also be used to compare the olfactory test scores between the 3 groups and paired t-test for evaluating for statistical within the groups. Probability values less than 5% (α=0.05) will be considered significant. Sub-analysis by etiology of olfactory loss will also be done using the same methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
* Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
* Group C: This study group will receive only standard of care .
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A: Vitamin A and Olfactory Retraining
Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
Vitamin A
The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
B: Vitamin A
Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
Vitamin A
The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
C: Standard of Care
Group C: This study group will receive only standard of care .
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin A
The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with baseline olfactory test scores \>30 using Sniffin sticks test.
* Patients with sinonasal tumors
* Patients with polyps or significant inflammation blocking access of medication to the olfactory cleft.
* Patients allergic to topical Vitamin A
* Cystic fibrosis or syndromic patients
* Patients with autoimmune diseases that have sinus manifestations or affect sinus function
* Patients with previous history of hypervitaminosis A
* Patients with Neurological Disease (e.g. stroke history, Parkinson's disease)
* Patients who are pregnant
19 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Paul's Hospital, Canada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amin Javer
Director, St. Paul's Sinus Centre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amin Javer, MD FRCSCFARS
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Paul Hospital
Vancouver, British Columbia, Canada
St Paul Sinus Centre
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H15-02095
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.